Valuation: Ocugen, Inc.

Market Cap 460M 404M 373M 343M 647M 44.4B 658M 4.46B 1.75B 21.72B 1.73B 1.69B 74.84B P/E 2026 *
-5.89x
P/E 2027 * -5.5x
Enterprise Value 398M 349M 322M 296M 559M 38.37B 568M 3.85B 1.51B 18.77B 1.49B 1.46B 64.68B EV / Sales 2026 *
91.1x
EV / Sales 2027 * 41.8x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day-2.21%
1 week-5.67%
Current month-13.07%
1 month+7.26%
3 months-28.11%
6 months-20.36%
Current year-1.48%
1 week 1.3
Extreme 1.3
1.48
1 month 1.26
Extreme 1.26
1.69
Current year 1.16
Extreme 1.16
2.72
1 year 0.93
Extreme 0.931
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Director/Board Member 71 05/06/2025
Chairman 62 27/09/2019
Director/Board Member 52 05/06/2025
Date Insider Type Main position Quantity % Market Cap.
6/15/26 A Buy

Chief Financial Officer

21,000 0.0062%
6/11/26 A Free

Director

170,100 0.0502%
6/11/26 A Free

Director

170,100 0.0502%
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%-5.67%+30.39%+121.67% 460M
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-1.94%+370.99%+572.60% 39.58B
-0.46%+2.18%+5.44%+61.01% 34.69B
-1.14%-1.76%+26.94%-9.93% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+69.28%+113.82% 15.36B
+1.17%+2.30%+15.87%+18.26% 14.05B
-2.25%+0.05%+15.77%-32.83% 13.02B
Average -1.57%-0.90%+59.37%+97.64% 24.41B
Weighted average by Cap. -1.44%-0.39%+75.82%+118.67%

Financials

2026 *2027 *
Net sales 4.37M 3.83M 3.54M 3.25M 6.14M 421M 6.24M 42.3M 16.58M 206M 16.4M 16.04M 710M 11.02M 9.66M 8.93M 8.21M 15.49M 1.06B 15.74M 107M 41.85M 520M 41.38M 40.47M 1.79B
Net income -76.84M -67.35M -62.26M -57.26M -108M -7.41B -110M -744M -292M -3.63B -289M -282M -12.49B -85.3M -74.76M -69.11M -63.56M -120M -8.23B -122M -826M -324M -4.02B -320M -313M -13.87B
Net Debt -62.5M -54.78M -50.64M -46.57M -87.87M -6.03B -89.28M -605M -237M -2.95B -235M -230M -10.16B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
20/07/26 $1.330 -2.21% 4,633,478
17/07/26 $1.360 -0.73% 3,844,188
16/07/26 $1.370 -4.20% 5,003,426
15/07/26 $1.430 0.00% 3,577,055
14/07/26 $1.430 +1.42% 4,964,447
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.330USD
Average target price
11.43USD
Spread / Average Target
+759.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock